Evaluation Improving Patient Outcomes in Seborrheic Dermatitis Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). April W. Armstrong, MD, MPH 5 4 3 2 1 Joseph F. Merola, MD, MMSc, FAAD, FACR 5 4 3 2 1 Susan C. Taylor, MD 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Describe the clinical characteristics and burden of seborrheic dermatitis 5 4 3 2 1 Assess strategies to recognize and diagnose seborrheic dermatitis in affected patients 5 4 3 2 1 Evaluate the mechanisms of action and latest clinical data associated with newer and emerging topical agents for seborrheic dermatitis 5 4 3 2 1 Outline evidence-based integrative strategies to manage challenging cases in seborrheic dermatitis 5 4 3 2 1 Describe the unmet needs and clinical manifestations associated with seborrheic dermatitis in skin of color 5 4 3 2 1 Evaluate the treatment considerations for seborrheic dermatitis in skin of color 5 4 3 2 1 Implement patient-centered and appropriately tailored treatment plans for patients with seborrheic dermatitis 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with Seborrheic Dermatitis on a monthly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage Seborrheic Dermatitis. Excellent Very Good Good Fair Poor Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Approximately______ of adult seborrheic dermatitis (SD) cases involve the scalp. 30% 50% 70% 90% Nearly 80% of patients in the phase 3 STRATUM trial treated with ______, an FDA-approved non-steroidal topical foam, achieved investigation global assessment (IGA) success at week 8. Crisaborole Difamilast Roflumilast Tazarotene PDE-4 inhibitors target which of the following mechanisms involved in SD pathogenesis? cAMP degradation IL-17 production NF-kB activation TNFα elevation How confident are you now in your ability to implement evidence-based integrative strategies to manage challenging cases in seborrheic dermatitis? Very confident Confident Somewhat confident Not very confident Not at all confident Based on my participation in this activity, I anticipate I will more often: (select all that apply) Assess the burden of SD and its impact on patient quality of life Utilize evidence-based and expert-recommended tools to evaluate SD and differentiate it from other inflammatory skin disorders Review current and emerging agents with novel MOAs and their role in targeting SD pathogenesis Other (please specify): Based on my participation in this activity, I anticipate I will more often: (select all that apply) Assess strategies to accurately evaluate SD on skin of color, with an understanding of distinct features that present on patients with darker skin tones Consider current and novel treatments for SD and their impact on the treatment of patients with skin of color Implement patient-centered approaches for the treatment of SD Other (please specify): Compared to lighter skin tones, SD on darker skin tones may present as ______. Pink-colored, oily patches Prurigo-like lesions Scaly, hypopigmented patches Violet or silver patches How confident are you now in your ability to assess and differentiate SD on patients of different skin tones, including patients with skin of color? Very confident Confident Somewhat confident Not very confident Not at all confident Please rate your ability now to implement patient-centered and personalized treatment plans for individuals with SD. Excellent Very good Good Fair Poor Previous
